ClinicalTrials.gg
CompletedNCT02952482Updated Jul 12, 2018

Newborn Screening for Adrenoleukodystrophy

An observational study in Adrenoleukodystrophy, sponsored by National Taiwan University Hospital. Completed at 1 site in Taiwan. Open to participants aged 2 Days to 3 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-07-12.

Sponsored by National Taiwan University Hospital · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
45,796
Ages
2 Days to 3 Months
Sex
All
01

Study summary

To test if the routine newborn screening dried blood spots can be used to test if elevation of C26:0 lysophosphatidylcholine (C26:0-lyso-PC), a status indicating adrenoleukodystrophy (ALD)

Read the detailed description

Parents of newborns will be invited to test if their newborns are affected with ALD. The routine newborn screening dried blood spots sample will be used to test the concentration of C26:0-lyso-PC . If positive of a screening test, further confirmation tests including physical examination and other methodology for ALD confirmation will be provided. Genetic counseling and treatment option will be provided, too.

02

Conditions studied

  • Adrenoleukodystrophy

Browse trials for

Keywords

  • adrenoleukodystrophy
  • C26:0-lyso-PC
03

In context

Adrenoleukodystrophy

68 studies on the registry are indexed under Adrenoleukodystrophy; 19 are open to participants now.

This study's enrollment of 45,796 is above the median of 120 across 19 observational studies indexed under Adrenoleukodystrophy.

Browse Adrenoleukodystrophy studies →

Lead sponsor

National Taiwan University Hospital is the lead sponsor of 2,615 studies on the registry; 576 are open to participants now.

Of its 11 completed or terminated interventional studies of FDA-regulated products, 2 (18%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
2 Days to 3 Months
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

newborns whose parents agree to be tested

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Babies born in Taiwan receive regular newborn screening suggested by Ministry of Heath and Welfare.
  • Parents or Legal Guardian sign in the form.

Exclusion criteria

Exclusion Criteria:

  • Parents or Legal Guardian do not agree to sign in the form.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
45,796 participants (actual)
Patient registry
No

Groups and cohorts

  • newborns testing for ALD

    newborns testing for ALD

    Procedure: newborns testing for ALD

Interventions

  • Procedurenewborns testing for ALD

    Routine newborn screening dried blood spots sample is used to test if elevation of C26:0-lyso-PC

06

What researchers measure

Primary outcomes

  1. numbers of newborn with ALD

    Time frame: 12 months

07

Study locations

1 site
  • National Taiwan University Hospital
    Taipei, 100, Taiwan
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2016, a primary completion of Aug 2017 and a completion of Aug 2017. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 31, 2016
First posted
Nov 2, 2016
Start
Nov 2016
Primary completionActual
Aug 2017
CompletionActual
Aug 2017
Last update
Jul 12, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 12, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02952482
Responsible party
Sponsor
First posted
Nov 2, 2016
Start date
Nov 2016
Primary completion
Aug 2017
Completion
Aug 2017
Last update
Jul 12, 2018

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion